Juniper Pharmaceuticals, Inc. Common Stock
JNP
JNP was delisted on the 13th of August, 2018.
35 hedge funds and large institutions have $13.6M invested in Juniper Pharmaceuticals, Inc. Common Stock in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 7 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
71% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 7
24% more capital invested
Capital invested by funds: $11M → $13.6M (+$2.6M)
13% more funds holding
Funds holding: 31 → 35 (+4)
95% less call options, than puts
Call options by funds: $36K | Put options by funds: $690K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$666K |
| 2 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
+$493K |
| 3 |
JIR
James Investment Research
Alpha,
Ohio
|
+$400K |
| 4 |
GF
Gabelli Funds
Rye,
New York
|
+$358K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$130K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Algert Global
San Francisco,
California
|
-$390K |
| 2 |
Renaissance Technologies
New York
|
-$278K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$128K |
| 4 |
ARTA
A.R.T. Advisors
New York
|
-$41.7K |
| 5 |
U
UBS
Zurich,
Switzerland
|
-$13K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ECM
26
Estabrook Capital Management
New York
| $10.8K | – | – | – |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $10K | +$9.11K | +1,318 | +1,117% |
|
|
OSAM
28
O'Shaughnessy Asset Management
Stamford,
Connecticut
| $6K | -$1.69K | -245 | -22% |
|
|
FAM
29
Formidable Asset Management
Cincinnati,
Ohio
| $6K | – | – | – |
|
30
AllianceBernstein
Nashville,
Tennessee
| $1K | – | – | – |
|
|
FWM
31
Focused Wealth Management
Newburgh,
New York
| $1K | +$553 | +80 | +64% |
|
|
LTFS
32
Ladenburg Thalmann Financial Services
Miami,
Florida
| $1K | +$553 | +80 | New |
|
33
BNP Paribas Financial Markets
Paris,
France
| $717 | – | – | – |
|
34
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $3 | – | – | – |
|
|
AG
35
Algert Global
San Francisco,
California
| – | -$390K | -59,063 | Closed |
|
|
36
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$128K | -19,463 | Closed |
|
37
Creative Planning
Overland Park,
Kansas
| – | +$7 | +1 | New |
|
JNP Hedge Fund Activity: Q1 2014 in Review
35 of the 3,464 institutional investors tracked by Wall St. Rank reported a position in Juniper Pharmaceuticals, Inc. Common Stock (JNP) for Q1 2014, worth a combined $13.6M — up 24% from $11M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new JNP positions and 2 closed out — a net gain of 4 holders — while 12 added to existing stakes and 7 trimmed.
The largest buyer was BlackRock Institutional Trust, adding an estimated $666K. The largest seller was Algert Global, exiting entirely with an estimated $390K sold.
- 35 institutional investors held Juniper Pharmaceuticals, Inc. Common Stock (JNP) as of Q1 2014, up from 31 in Q4 2013.
- Funds reported $13.6M of Juniper Pharmaceuticals, Inc. Common Stock stock for Q1 2014, up 24% quarter-over-quarter.
- 6 funds opened new Juniper Pharmaceuticals, Inc. Common Stock positions in Q1 2014 and 2 closed out, a net change of +4 holders.
- The largest Juniper Pharmaceuticals, Inc. Common Stock buyer in Q1 2014 was BlackRock Institutional Trust, an estimated $666K added.
- The largest Juniper Pharmaceuticals, Inc. Common Stock seller in Q1 2014 was Algert Global, an estimated $390K sold.
Based on aggregated 13F filings for Q1 2014.